MDR Class IIb in place. TÜV Süd notified body engaged. CE-mark renewed. ISO 13485 current. The German medtech CEO assumes the bridge is shorter than it is. The bridge has four FDA-side pathways, a US clinical-evidence layer, a US KOL architecture, a US payer-coding map, and a US IDN procurement reader who reads everything in US-legible commercial form. The regulatory pathway is FDA counsel. The commercial bridge is the marketing work.
BRIDGE.
The German medtech operator typically holds a CE-marked device under MDR, ISO 13485 quality-management certification, multi-year European hospital references, and a notified-body relationship (TÜV Süd, TÜV Rheinland, BSI, DEKRA, MDC). Names that fit the archetype: Siemens Healthineers (electromedical lines), Brainlab, Karl Storz, Richard Wolf, Aesculap under B. Braun, Biotronik, Otto Bock, Carl Zeiss Meditec, Drägerwerk. Many also have a smaller-cap cohort of family-controlled medtech specialists across Bavaria, Baden-Württemberg, and NRW.
The US bridge is incomplete for most of the cohort. The FDA pathway is selected, partially executed, or pending. US clinical evidence is partial. US KOL relationships exist transactionally rather than as architecture. US payer and reimbursement positioning is under-resourced. US IDN procurement readers are unfamiliar with the device. Per GTAI tracking, German medtech exports to North America in 2025-2026 remain at multi-year highs, while US clinical-evidence presence remains below where the export volume would suggest.
The MDR-to-FDA bridge has a regulatory side and a commercial side. FDA counsel handles the pathway. Marketing handles the commercial surface. Both sides need to ship together.
MDR (Regulation EU 2017/745) governs CE-marking in the EU and replaced the prior MDD framework, raising evidentiary requirements, tightening post-market surveillance, and introducing the European Database on Medical Devices (Eudamed). None of this satisfies the FDA.
A German medtech firm with a Class IIb CE-marked device under MDR has not satisfied the FDA. The FDA reads US predicate, US classification, US clinical evidence, US post-market surveillance. The MDR clinical evaluation report does not auto-port to FDA clinical-data acceptability. The German firm's commercial frame in the US must surface the FDA pathway, the named timeline, and the US clinical-evidence position in US-legible form so US health-system procurement and KOL conversations can proceed in parallel with the regulatory submission.
Pathway selection is FDA regulatory counsel work. The marketing work is to surface the selected pathway, the named timeline, and the US clinical-evidence position in the US-facing materials so the US procurement reader, the US KOL, and the US payer can be brought along in parallel with the submission.
"MDR Class IIb means cleared in the EU. FDA reads US predicate, US classification, US clinical evidence, US post-market. The bridge is two regimes."House reading on MDR-to-FDA crossing
ISO 13485 is the international medical-device quality-management standard. FDA QSR under 21 CFR Part 820 is the US regulatory requirement. The FDA has finalised harmonisation moving 21 CFR Part 820 toward ISO 13485, but with US-specific overlays that include unique device identification, complaint handling, and US-specific reporting. ISO 13485 supports but does not equal FDA QSR.
The German medtech firm's ISO 13485 certification supports FDA preparation. It does not substitute for QSR-specific compliance work. The compliance gap analysis, the QSR alignment plan, and the FDA pre-approval inspection readiness all sit with FDA regulatory counsel and quality-systems specialists. The marketing surface flags the ISO 13485 baseline and the QSR alignment work openly, so the US procurement reader is not surprised.
FDA clearance is the gate. The US commercial bridge is the work on the gate that marketing actually owns.
| Before rebuild (MDR-leading register) | After rebuild (US-commercial-ready) |
|---|---|
| CE-mark and MDR class lead the materials | FDA pathway, named timeline, US clinical-evidence plan at the front |
| European hospital references in the lead | US IDN and US clinical-investigator references in the lead where they exist; honest pilot stage where they do not |
| European clinical-evaluation report referenced | US clinical-evidence plan named, US trial sites named, US PI engagement named |
| European KOL endorsement (DGCH, DGOOC, etc.) | US KOL architecture: named US opinion leaders, named US academic medical centers, US society memberships |
| European reimbursement, DRG referenced | US reimbursement: CMS CPT, HCPCS, ICD-10-PCS, MS-DRG mapping |
| EUR pricing, European warranty | USD pricing, US warranty in US-legible form, US service-footprint commitments |
US IDN procurement (HCA Healthcare, CommonSpirit, Ascension, Mass General Brigham, Cleveland Clinic, Kaiser, Mayo, UPMC) and US GPO procurement (Vizient, Premier, HealthTrust, Intalere) read the materials against FDA clearance, US clinical evidence, US KOL endorsement, US service footprint, and US reimbursement coding. The German medtech firm without US clinical evidence and without US-coded reimbursement carries gaps the GPO RFP cannot ignore. The fix is to surface US clinical-evidence development plans, US KOL relationships under construction, and US reimbursement positioning in US-legible commercial terms even where the work is in progress.
Stage one: diagnose where the bridge breaks. Regulatory pathway selection. Clinical-evidence portability. US payer positioning. US KOL architecture. US IDN procurement readiness. Where the firm is in each.
Stage two: correct the signal. Surface the FDA pathway, named timeline, US clinical-evidence plan, US KOL relationships under construction, US payer and reimbursement positioning. Move MDR and CE-mark to supporting context. Move European references and DRG to supporting context.
Stage three: rebuild the materials. US-facing site, US-procurement-facing materials for IDN and GPO, US KOL-facing materials, US payer-facing materials, US sales-cycle templates, US service-footprint commitments, US-facing principal page with US clinical-affairs counterpart.
This work runs inside a Market Entry Sprint (six to ten weeks, one US IDN target and the US-facing materials shipped), a Cross-Border Build (three to six months, multi-architecture rebuild across IDN, GPO, KOL, and payer), or a Group Partnership (monthly retainer, twelve-month minimum, for medtech groups with multiple device lines). Pricing is confirmed in discovery, not on the public site.
"510(k) submissions accounted for the majority of FDA medical-device clearances. De Novo and PMA pathways carry materially longer timelines and additional clinical-evidence requirements. The Q-Submission programme is available for pre-submission feedback at any stage."
"if your product doesn't plug directly into the specific US workflow, you are asking them to change their entire workflow just to test your tool."
Independent regimes. MDR EU 2017/745 governs CE-marking. FDA pathways are 510(k), De Novo, PMA, or IDE-PMA. ISO 13485 supports but does not equal FDA QSR. MDR clinical evidence does not auto-port to FDA acceptability.
ISO 13485 is the international medical-device QMS standard. QSR is the US regulatory requirement. The FDA is harmonising 21 CFR Part 820 toward ISO 13485 with US-specific overlays. ISO 13485 supports but does not equal QSR.
510(k) on a US predicate. De Novo for novel low-to-moderate risk. PMA for Class III. IDE-then-PMA when a significant-risk clinical study is needed. Pathway selection is FDA regulatory counsel work.
No. FDA 510(k) and PMA submissions, De Novo, IDE applications, Q-Submission filings, FDA QSR compliance, MDUFA fee filings, ISO 13485 audits, MDR clinical evaluation reports, and notified-body engagement belong with FDA regulatory counsel and notified-body specialists.
US category positioning, US clinical-evidence narrative, US KOL architecture, US payer and reimbursement positioning, US IDN and GPO procurement frame, US-facing site, materials, bios, and commercial cadence.
Diagnose where the bridge breaks. Correct the signal: surface the FDA pathway, named timeline, US clinical-evidence plan, US KOL relationships, US payer and reimbursement positioning. Rebuild the materials.
Designation under FDARA Section 3051 provides expedited review and increased FDA engagement for life-threatening or irreversibly debilitating conditions. Accelerates timelines. Does not change classification or replace clinical evidence requirements.
Inquiry through the contact form and a discovery conversation. Send the device classification (EU and intended FDA), the FDA pathway counsel has scoped, the US clinical-evidence plan if drafted, US KOL relationships if any, and the US-facing site if any. Response within one business day.
No FDA 510(k) or PMA submissions. No De Novo classification requests. No IDE applications. No Q-Submission filings. No FDA pre-submission meetings. No FDA QSR compliance gap analysis. No FDA pre-approval or post-approval inspections. No 21 CFR Part 11 compliance. No MDUFA fee filings. No ISO 13485 certification audits. No MDR clinical evaluation reports. No EU Notified Body engagement. No CMS reimbursement coding decisions. No US health-system contract negotiation. These belong with FDA regulatory counsel, notified-body specialists, and US reimbursement specialists. When a marketing decision intersects FDA, MDR, ISO 13485, QSR, or US reimbursement, the firm flags and defers.
Sources cited on this page: FDA 510(k) device guidance, FDA Q-Submission programme, Roland Berger Mittelstand survey 2025-2026, Germany Trade and Invest (GTAI), US Centers for Medicare and Medicaid Services (CMS), White & Case M&A Explorer 2026, US BEA FDI inflows by country 2025, Forrester B2B AI buyer-agent forecast end-2026, MDR glossary.